NSE ScannerPharmaceuticals · Biotechnology · NSE: ANTHEM · data 2026-10-31
Anthem Biosciences Limited
In plain words
Price: 15.2% below its 52-week high of ₹977.55.
Delivery: 52.9% of traded shares were kept for delivery over the last 10 sessions, against 55.2% over the last 60.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹2,002 cr |
| Net profit (last 12 months) | ₹576 cr |
| Sales growth, 3 years (yearly) | 26.2% |
| Profit growth, 3 years (yearly) | 15.4% |
At a glance
Promoters 71.4% (-3.3 pts in a year), pledged 0.0%, institutions 15.9%.
P/E 81.7, dividend yield 0.2%. Price relative to earnings and book value (low is cheaper, not better).
ROE 21.7%, ROCE 26.0%, operating margin 32.7%: how much profit it earns on the money it uses.
Debt/equity 0.02, Profit growth 15.4% and sales growth 26.2% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
- High return on equity (21.7%).
- Healthy operating margin (32.7%).
- Profit grew 15.4% a year over 3 years.
- Promoters cut their holding by 3.3 points in a year.
- Expensive on earnings (P/E 81.7).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
16/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Delivery 55.9% over the last 20 sessions vs 56.2% in the 40 before (0.99x); shares delivered per day 0.45x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 11/15: 18 schemes hold it, about ₹1,421 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Dividend
- 25 Jun 26Dividend Dividend ₹2 (ex-date) +0.8% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 71.40% | 71.42% | 74.68% | 74.69% |
| Foreign institutions (FII) | 3.79% | 2.58% | 1.28% | 1.36% |
| Domestic institutions (DII) | 12.10% | 13.48% | 11.55% | 7.60% |
| Mutual funds | 9.25% | 11.15% | 10.12% | 6.89% |
| Retail investors | 1.83% | 1.78% | 1.66% | 1.89% |
| Number of shareholders | 1,76,209 | 1,73,273 | 1,80,220 | 1,99,492 |
Common questions
How much do promoters hold in Anthem Biosciences Limited?
Promoters held 71.40% of Anthem Biosciences Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Anthem Biosciences Limited debt-free?
Its latest reported debt-to-equity ratio is 0.02, which is very low.
What is Anthem Biosciences Limited's P/E ratio?
About 81.7, based on the last 12 months' earnings and a price of ₹828.8 (data 2026-10-31).
What is the 52-week high and low of Anthem Biosciences Limited?
The 52-week high is ₹977.55 and the 52-week low is ₹579.15.
Mutual funds holding Anthem Biosciences Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 18 schemes holding about ₹1,421 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| SBI Midcap Fund | SBI Mutual Fund | 1.59% | ₹370 cr |
| ADITYA BIRLA SUN LIFE FLEXI CAP FUND | Aditya Birla Sun Life Mutual Fund | 0.75% | ₹210 cr |
| SBI MNC Fund | SBI Mutual Fund | 2.96% | ₹189 cr |
| SBI Healthcare Opportunities Fund | SBI Mutual Fund | 2.75% | ₹161 cr |
| NIPPON INDIA PHARMA FUND | Nippon India Mutual Fund | 1.19% | ₹109 cr |
| Mirae Asset Small Cap Fund | Mirae Asset Mutual Fund | 1.83% | ₹107 cr |
| SBI RETIREMENT BENEFIT FUND - AGGRESSIVE PLAN | SBI Mutual Fund | 2.08% | ₹64 cr |
| Mirae Asset Flexi Cap Fund | Mirae Asset Mutual Fund | 1.15% | ₹50 cr |
| ADITYA BIRLA SUN LIFE AGGRESSIVE HYBRID FUND | Aditya Birla Sun Life Mutual Fund | 0.65% | ₹44 cr |
| Mirae Asset Healthcare Fund | Mirae Asset Mutual Fund | 0.93% | ₹33 cr |
| SBI Quality Fund | SBI Mutual Fund | 1.08% | ₹28 cr |
| SBI RETIREMENT BENEFIT FUND - AGGRESSIVE HYBRID PLAN | SBI Mutual Fund | 1.65% | ₹26 cr |
| ADITYA BIRLA SUN LIFE SPECIAL OPPORTUNITIES FUND | Aditya Birla Sun Life Mutual Fund | 1.08% | ₹15 cr |
| ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND | Aditya Birla Sun Life Mutual Fund | 1.13% | ₹12 cr |
| SBI RETIREMENT BENEFIT FUND - CONSERVATIVE HYBRID PLAN | SBI Mutual Fund | 0.83% | ₹2 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Anthem Biosciences Limited | ₹828.8 | ₹46,685 cr | 81.7 | — | 21.7% | 26% | 0.02 | +13.6% |
| Rubicon Research Limited | ₹1,610.5 | ₹26,650 cr | 92.7 | — | 27% | 32.4% | 0.24 | +168.0% |
| Akums Drugs and Pharmaceuticals Limited | ₹731.7 | ₹11,520 cr | 38.4 | — | 8% | 9.8% | 0.05 | +55.4% |
| Fermenta Biotech Ltd | ₹417.55 | ₹1,229 cr | 20.2 | — | 18.7% | 20.8% | 0.28 | +34.7% |
| Fabtech Technologies Limited | ₹123.9 | ₹547 cr | 14.1 | 1.3 | 12.9% | 9.1% | 0.17 | -48.7% |
| Haleos Labs Ltd. | ₹1,394.4 | ₹411 cr | 26.7 | — | 8.4% | 10.4% | 0.52 | +22.2% |
Compare ANTHEM with RUBICON in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open ANTHEM in NSE Scanner →